Insulet Corporation management check
PODD · Health Care · Health Care Equipment · CEO Ashley McEvoy
Filings as of
3 good · 1 to watch · 3 flagged, across the seven questions below.
- Good
Have owners done well?
Beat its chosen peers$100 invested at the start of fiscal 2021 grew to $111, against $99 for the peer group the company picked itself.
- Watch
Does pay follow performance?
Pay only loosely tracked returnsOver 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.23 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Flag
What does the CEO cost owners?
7.6% of net income$18.9m of reported pay in fiscal 2025, against $247.1m of net income.
- Good
Do they own the stock?
Insiders are buyingThe CEO holds 23,731 shares, directly or through trusts (unvested awards not counted): about 0.2 years of pay. 3 insiders bought $1.1m on the open market in the last six months, with their own money, near the lows. Sales: $60k.
- Good
Are owners being diluted?
Share count shrinkingDiluted shares changed -1.2% a year over the last three fiscal years. Stock-based pay was 2.3% of revenue in the latest year.
- Flag
Is leadership stable?
3 CEOs in the pay tableCEOs in the pay table: Shacey Petrovic, James Hollingshead, Ashley McEvoy. 15 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- Flag
Are the books clean?
Red flags on file2 auditor changes (8-K 4.01) since 2021.
Against the S&P 500
Each check's score (0–100) and how it compares: the share of ranked S&P 500 companies it matches or beats, and the median in Health Care.
| Check | Score | At or above | Sector median |
|---|---|---|---|
| Owner returns | 65 | 26 | |
| Pay for performance | 62 | 85 | |
| CEO cost | 0 | 44 | |
| Skin in the game | 20 | 46 | |
| Dilution | 65 | 68 | |
| Stable leadership | 0 | 70 | |
| Clean books | 15 | 100 |
Closest peers
Others in Health Care Equipment, by management score. Insulet Corporation is 59th of 60 in its sector.
- 115ABTAbbott Laboratories75
- 149SYKStryker Corporation72
- 156ISRGIntuitive Surgical72
- 188IDXXIdexx Laboratories69
- 192BSXBoston Scientific69
- 246RVTYRevvity64
- 256GEHCGE HealthCare64
- 294RMDResMed62
- 321STESteris60
- 353BDXBecton Dickinson58
Pay versus performance
From the proxy statement filed April 6, 2026. "Actually paid" values stock awards at the share price, so it rises and falls with the stock.
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Ashley McEvoy, James Hollingshead | $18.9m | $25.2m | $3.8m | $111 | $99 | $247.1m |
| 2024 | James Hollingshead | $13.3m | $32.7m | $3.3m | $102 | $81 | $418.3m |
| 2023 | James Hollingshead | $12.4m | $12.8m | $2.8m | $85 | $82 | $206.3m |
| 2022 | James Hollingshead, Shacey Petrovic | $15.7m | $16.1m | $3.4m | $115 | $77 | $4.6m |
| 2021 | Shacey Petrovic | $9.7m | $9.1m | $2.6m | $104 | $96 | $16.8m |
The board says pay is tied most to Adjusted revenue. Its other key measures: Adjusted Revenue, Adjusted EBIT, Relative TSR.
Insiders and the CEO's stake
Ashley McEvoy (President and CEO) held 23,731 shares directly after their latest Form 4 on Aug 21, 2026, roughly $3.5m at that filing's price.
3 insiders bought $1.1m on the open market in the last six months, with their own money, near the lows. Sales: $60k.
- BoughtElizabeth H WeathermanDirector$497kJun 3, 2026
- BoughtTimothy C. StonesiferDirector$400kJun 3, 2026
- BoughtAshley McEvoyPresident and CEO$162kAug 21, 2026
- SoldLuciana BorioDirector$60kJun 3, 2026
Leadership and governance on file
- Sep 16, 2026Leadership change8-K 5.02
- Sep 10, 2026Leadership change8-K 5.02
- Jun 25, 2026Leadership change8-K 5.02
- Mar 4, 2026Leadership change8-K 5.02
- Feb 24, 2026Auditor change8-K/A 4.01
- Dec 19, 2025Auditor change8-K 4.01
- Dec 17, 2025Leadership change8-K 5.02
- Oct 23, 2025Leadership change8-K 5.02
- Sep 16, 2025Leadership change8-K 5.02
- May 28, 2025Leadership change8-K 5.02
- Apr 28, 2025Leadership change8-K 5.02
- Apr 9, 2025Leadership change8-K/A 5.02
Latest shareholder vote results: May 21, 2026, including the say-on-pay vote.
Where the money went
Over 2021–2025: $59.6m returned to owners in buybacks and dividends, 7% of net income, and $255.7m of pay in stock.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.0bn | $1.1bn | $1.7bn | $2.1bn | $2.7bn |
| Net income | $16.8m | $4.6m | $206.3m | $418.3m | $247.1m |
| Stock-based pay | $34.4m | $40.9m | $48.4m | $69.3m | $62.7m |
| Buybacks | — | — | $0 | $0 | $59.6m |
| Dividends | — | — | — | — | — |
| Diluted shares | 69m | 70m | 74m | 74m | 72m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.